<DOC>
	<DOCNO>NCT02549027</DOCNO>
	<brief_summary>The purpose randomize , double-blind , placebo-controlled , 5-period crossover study assess effect single oral dos MK-1064 latency persistent sleep ( LPS ) measure polysomnography ( PSG ) healthy young male participant , evaluate safety tolerability single oral dos MK-1064 MK-6096 healthy young male participant . The primary efficacy hypothesis least one dose MK-1064 superior placebo decrease LPS healthy male participant assess PSG .</brief_summary>
	<brief_title>A Study Evaluate Effects Single Doses MK-1064 MK-6096 Polysomnography ( PSG ) ( MK-1064-003 )</brief_title>
	<detailed_description />
	<criteria>Body Mass Index ( BMI ) ≤31 kg/m^2 In good health base medical history , physical examination , vital sign measurement , laboratory safety test Nonsmoker use nicotine nicotinecontaining product least 6 month No history sleep disorder Has use prescription counter sedation alert medication 4 week prior screen Participant usual bedtime 8:00 PM 12:00 AM Participant total sleep duration ≥6.5 ≤9 hour 4 week prior screen Male participant female partner ( ) childbearing potential must agree use medically acceptable method contraception study 90 day last dose study drug Mentally legally incapacitate , significant emotional problem screen expect conduct study history clinically significant psychiatric disorder within last 10 year History persistent sleep abnormality ( include difficulty fall asleep , difficulty stay asleep ) last 3 month , history obstructive sleep apnea , restless leg syndrome , narcolepsy History clinically significant sleep disorder within last 5 year History circadian rhythm sleep disorder , clinically important parasomnia , primary insomnia History repeat fall fracture secondary fall within past 2 year Participant work night shift able avoid night shift work minimum 1 week prior screen duration study Participant travel across 3 time zone ( transmeridian travel ) last 2 week prior study Is regular user sedativehypnotic agent History clinically significant endocrine , gastrointestinal , cardiovascular , hematological , hepatic , immunological , renal , respiratory , genitourinary abnormality diseases History stroke , peripheral neuropathy , chronic seizure clinically significant neurological disorder cognitive impairment History cancer History cataplexy Participant unable refrain anticipates use medication , include prescription nonprescription drug herbal remedy , begin approximately 2 week prior administration initial dose study drug throughout study Participant consume &gt; 3 serving alcohol day Participant consume &gt; 6 caffeine serving day Participant major surgery , donate lose 1 unit blood ( approximately 500 mL ) within 4 week prior screen , participate another investigational study within 3 month prior first dose study drug History significant multiple and/or severe allergy anaphylactic reaction significant intolerability prescription nonprescription drug food Is currently regular user illicit drug history drug ( include alcohol ) abuse within 2 year screen</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>January 2016</verification_date>
</DOC>